FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2808422366> ?p ?o ?g. }

• W2808422366 endingPage "2291" @default.
• W2808422366 startingPage "2280" @default.
• W2808422366 abstract "The oncostatin M (OSM) pathway drives fibrosis, inflammation and vasculopathy, and is a potential therapeutic target for inflammatory and fibrotic diseases. The aim of this first-time-in-human experimental medicine study was to assess the safety, tolerability, pharmacokinetics and target engagement of single subcutaneous doses of GSK2330811, an anti-OSM monoclonal antibody, in healthy subjects.This was a phase I, randomized, double-blind, placebo-controlled, single-dose escalation, first-time-in-human study of subcutaneously administered GSK2330811 in healthy adults (NCT02386436). Safety and tolerability, GSK2330811 pharmacokinetic profile, OSM levels in blood and skin, and the potential for antidrug antibody formation were assessed. The in vivo affinity of GSK2330811 for OSM and target engagement in serum and skin blister fluid (obtained via a skin suction blister model) were estimated using target-mediated drug disposition (TMDD) models in combination with compartmental and physiology-based pharmacokinetic (PBPK) models.Thirty subjects were randomized to receive GSK2330811 and 10 to placebo in this completed study. GSK2330811 demonstrated a favourable safety profile in healthy subjects; no adverse events were serious or led to withdrawal. There were no clinically relevant trends in change from baseline in laboratory values, with the exception of a reversible dose-dependent reduction in platelet count. GSK2330811 exhibited linear pharmacokinetics over the dose range 0.1-6 mg kg-1 . The estimated in vivo affinity (nM) of GSK2330811 for OSM was 0.568 [95% confidence interval (CI) 0.455, 0.710] in the compartmental with TMDD model and 0.629 (95% CI 0.494, 0.802) using the minimal PBPK with TMDD model.Single subcutaneous doses of GSK2330811 were well tolerated in healthy subjects. GSK2330811 demonstrated sufficient affinity to achieve target engagement in systemic circulation and target skin tissue, supporting the progression of GSK2330811 clinical development." @default.
• W2808422366 created "2018-06-21" @default.
• W2808422366 creator A5007556436 @default.
• W2808422366 creator A5033409826 @default.
• W2808422366 creator A5042523849 @default.
• W2808422366 creator A5047834135 @default.
• W2808422366 creator A5059860640 @default.
• W2808422366 creator A5065998248 @default.
• W2808422366 creator A5066687267 @default.
• W2808422366 creator A5079783310 @default.
• W2808422366 creator A5085213609 @default.
• W2808422366 date "2018-07-12" @default.
• W2808422366 modified "2023-10-16" @default.
• W2808422366 title "<i>In vivo</i>affinity and target engagement in skin and blood in a first-time-in-human study of an anti-oncostatin M monoclonal antibody" @default.
• W2808422366 cites W1536263647 @default.
• W2808422366 cites W159719701 @default.
• W2808422366 cites W1718175705 @default.
• W2808422366 cites W1898884874 @default.
• W2808422366 cites W1965479467 @default.
• W2808422366 cites W1968814677 @default.
• W2808422366 cites W1983632874 @default.
• W2808422366 cites W1991687240 @default.
• W2808422366 cites W2007936358 @default.
• W2808422366 cites W2023612812 @default.
• W2808422366 cites W2028763529 @default.
• W2808422366 cites W2032754679 @default.
• W2808422366 cites W2048164597 @default.
• W2808422366 cites W2062826169 @default.
• W2808422366 cites W2073807783 @default.
• W2808422366 cites W2093712437 @default.
• W2808422366 cites W2117564935 @default.
• W2808422366 cites W2137209912 @default.
• W2808422366 cites W2137535890 @default.
• W2808422366 cites W2146721644 @default.
• W2808422366 cites W2152295044 @default.
• W2808422366 cites W2163848645 @default.
• W2808422366 cites W2322800034 @default.
• W2808422366 cites W2532646138 @default.
• W2808422366 cites W2594378211 @default.
• W2808422366 cites W2604780989 @default.
• W2808422366 cites W2743743960 @default.
• W2808422366 cites W2766119667 @default.
• W2808422366 cites W2771328536 @default.
• W2808422366 cites W2794420673 @default.
• W2808422366 cites W2808422366 @default.
• W2808422366 cites W28215347 @default.
• W2808422366 cites W3009538581 @default.
• W2808422366 cites W4211149849 @default.
• W2808422366 doi "https://doi.org/10.1111/bcp.13669" @default.
• W2808422366 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6138480" @default.
• W2808422366 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29900565" @default.
• W2808422366 hasPublicationYear "2018" @default.
• W2808422366 type Work @default.
• W2808422366 sameAs 2808422366 @default.
• W2808422366 citedByCount "31" @default.
• W2808422366 countsByYear W28084223662019 @default.
• W2808422366 countsByYear W28084223662020 @default.
• W2808422366 countsByYear W28084223662021 @default.
• W2808422366 countsByYear W28084223662022 @default.
• W2808422366 countsByYear W28084223662023 @default.
• W2808422366 crossrefType "journal-article" @default.
• W2808422366 hasAuthorship W2808422366A5007556436 @default.
• W2808422366 hasAuthorship W2808422366A5033409826 @default.
• W2808422366 hasAuthorship W2808422366A5042523849 @default.
• W2808422366 hasAuthorship W2808422366A5047834135 @default.
• W2808422366 hasAuthorship W2808422366A5059860640 @default.
• W2808422366 hasAuthorship W2808422366A5065998248 @default.
• W2808422366 hasAuthorship W2808422366A5066687267 @default.
• W2808422366 hasAuthorship W2808422366A5079783310 @default.
• W2808422366 hasAuthorship W2808422366A5085213609 @default.
• W2808422366 hasBestOaLocation W28084223661 @default.
• W2808422366 hasConcept C111113717 @default.
• W2808422366 hasConcept C112705442 @default.
• W2808422366 hasConcept C126322002 @default.
• W2808422366 hasConcept C142724271 @default.
• W2808422366 hasConcept C150903083 @default.
• W2808422366 hasConcept C197934379 @default.
• W2808422366 hasConcept C204787440 @default.
• W2808422366 hasConcept C207001950 @default.
• W2808422366 hasConcept C27081682 @default.
• W2808422366 hasConcept C2778375690 @default.
• W2808422366 hasConcept C71924100 @default.
• W2808422366 hasConcept C86803240 @default.
• W2808422366 hasConcept C98274493 @default.
• W2808422366 hasConceptScore W2808422366C111113717 @default.
• W2808422366 hasConceptScore W2808422366C112705442 @default.
• W2808422366 hasConceptScore W2808422366C126322002 @default.
• W2808422366 hasConceptScore W2808422366C142724271 @default.
• W2808422366 hasConceptScore W2808422366C150903083 @default.
• W2808422366 hasConceptScore W2808422366C197934379 @default.
• W2808422366 hasConceptScore W2808422366C204787440 @default.
• W2808422366 hasConceptScore W2808422366C207001950 @default.
• W2808422366 hasConceptScore W2808422366C27081682 @default.
• W2808422366 hasConceptScore W2808422366C2778375690 @default.
• W2808422366 hasConceptScore W2808422366C71924100 @default.
• W2808422366 hasConceptScore W2808422366C86803240 @default.
• W2808422366 hasConceptScore W2808422366C98274493 @default.
• W2808422366 hasFunder F4320307773 @default.

• next